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Abstract 
Background: The aim of this study was to investigate the clinical significance of three immune cell‑related transcrip‑
tion factors, T‑bet, GATA‑3 and Bcl‑6 in bladder cancer in Tunisian patients.
Methods: Expression of T‑bet, GATA‑3 and Bcl‑6 genes was assessed using RT‑qPCR in 65 bladder cancers from 
patients: 32 being diagnosed as low‑ and medium‑grade, 31 as high‑grade, 25 as muscle invasive stage and 39 as 
non‑muscle invasive stage. Gene expression was statistically correlated according to the grade, the stage, tobacco 
consumption, the BCG response and disease severity.
Results: T‑bet levels in patients with high‑grade bladder cancer were significantly elevated compared to patients 
with low‑ or medium‑grade bladder cancer (p = 0.005). In invasive carcinoma (T2–T4), the T‑bet levels were signifi‑
cantly higher than in superficial non‑invasive bladder tumors (Tis, Ta, and T1) (p = 0.02). However, T‑bet is predictive of 
the response to BCG. Its expression is high in good responders to BCG (p = 0.02). In contrast, the expression of GATA‑3 
and Bcl‑6 in non‑invasive carcinoma (p = 0.008 and p = 0.0003) and in patients with low‑ and medium‑grade cancers 
(p = 0.001 and p < 0.0001) is significantly higher than in invasive bladder tumors and in patients with high‑grade 
bladder carcinoma, respectively. In addition, heavy smokers, whose tumors express low levels of GATA‑3 and Bcl‑6, are 
poor responders to BCG (p = 0.01 and p = 0.03). Finally, better patient survival correlated with GATA‑3 (p = 0.04) and 
Bcl‑6 (p = 0.04) but not T‑bet expression.
Conclusions: Our results suggest that T‑bet expression in bladder tumors could be a positive prognostic indicator of 
BCG therapy, even if high levels are found in high‑grade and stage of the disease. However, GATA‑3 and Bcl‑6 expres‑
sion could be considered as predictive factors for good patient survival.
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Background
Global analysis of cancers revealed the importance of 
the adaptive immune cell response against tumors for 
cancer patient survival. However, the clinical outcome 
depends on the nature, functional orientation, density 
and location of immune cells within the tumor micro-
environment [1]. For instance, ample clinical evidence 
shows that longer survival of cancer patients is associ-
ated with increased expression of genes characteristic 
of type 1 effector T cells, in particular the T-box master 
transcription factor regulator (T-bet) [2, 3]. Although 
T-bet is the master regulator of Th1 cell differentiation, 
it is expressed in multiple cells of the innate and adaptive 
immune system, including innate lymphoid cells (ILCs) 
[4, 5]. CD8+-infiltrating lymphocytes are also predictive 
of survival in muscle-invasive urothelial carcinoma [6] 
and are associated with a favorable prognosis in ovar-
ian cancer [7]. This contrasts with the accumulation of 
tumor-infiltrating regulatory T cells (Tregs), where it is 
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attested that the master regulator of Treg differentiation 
Foxp-3 is expressed. This creates an immunosuppressive 
microenvironment leading to tumor progression [8]. This 
is due to the ability of Treg cells to dampen the activity 
of CD4+ and CD8+ T cells, as well as natural killer (NK) 
cells, mainly by the release of transforming growth fac-
tor β (TGFβ1) and IL-10 [9]. Other adaptive cells are 
differently associated to cancer patient outcome. The 
Th2 response, evidenced inter alia by the expression of 
GATA-3, was associated with tumor immune evasion in 
a mouse study [10], but was not associated with a clinical 
outcome in human studies [11, 12] or in patient’s prog-
nosis [13]. Patients with a low Th17 response had a better 
disease-free survival [13], whereas Th17 cells increased 
with advanced gastric cancer [14]. The opposite effect 
was observed for ovarian cancer [15]. Concerning folli-
cular helper T cells (Tfh), an additional effector subset of 
T helper lymphocytes whose development is controlled 
by the B-cell lymphoma 6 transcription factor (Bcl-6), 
the presence of Tfh was high in various human cancers 
including malignancies in the lymphoid system [16]. 
Where the Tfh presence is significant, it has been associ-
ated with a better patient cancer outcome (breast cancer) 
[17], whereas a decreased proportion of Tfh was associ-
ated with increased hepatocellular carcinoma disease 
progression [18].
In the field of bladder cancer, few studies have 
addressed the role of immune cells in anti-tumor or pro-
tumor activity and the correlation between those infil-
trates and the clinical outcome [6, 19, 20].
Bladder cancer is the ninth most common malignancy 
worldwide, with its highest incidence rates in Western 
countries [21]. In Tunisia, bladder cancer is the second 
cause of cancer in the Tunisian male. The most effective 
therapy against superficial bladder cancer is intra-vesicle 
infiltration with Bacillus Calmette Guérin (BCG) [22]. 
However, some recurrence and progression occur after 
this therapy, which renders the response to BCG unpre-
dictable. Hence, it is necessary to pinpoint reliable pre-
dictive biomarkers that could identify groups at elevated 
risk of treatment failure for a specific therapy.
The aim of this study is to assess the prognostic value 
of three genes in tumors from bladder cancer patients in 
Tunisia: T-bet, GATA-3 and Bcl-6. We found that upon 
disease progression, patients with high expression levels 
of T-bet were related to invasive and high grade of the 
disease, but were good responders to BCG. In contrast, 
reductions in Bcl-6 and GATA-3 expression correlated 
with invasive and high-grade of bladder cancer and were 
associated with a decrease in disease-free survival. Our 
results suggest that Th1−, Th2− and Tfh− associated 
gene expression could represent potential prognostic 
markers in patients with bladder cancer.
Methods
Patients and samples
A total of 65 patients with bladder carcinoma, for 
whom transurethral resections were realized at the 
Urology Department of Charles Nicolle Hospital 
(Tunis, Tunisia) between 1999 and 2012. Informed 
consent was obtained from all patients before their 
enrolment in the study. This study is in agreement 
with the Declaration of Helsinki and was approved by 
the Ethical Committee of the Tunis Pasteur Institute. 
All patients were from the North of Tunisia: 93.84 % of 
them were men and 6.15 % were women, and the mean 
age at diagnosis was 65.63 ± 13.13 years. Histopatho-
logical grading and staging were performed accord-
ing to the WHO and TNM classification, respectively 
(Table 1).
RNA extraction from tumors
Bladder tumor samples ranging from stage and grade 
according to the TNM classification were obtained after 
surgical removal and 65 tissues samples were stored at 
−80  °C until the extraction of RNA. Total RNA from 
tumor tissue was isolated with TRIzol reagent (Invit-
rogen) according to the manufacturer’s protocol. After 
determination of the quality and concentration of the 
Table 1 Characteristics of TCC tumor samples and patient 
information
TCC transitional cell carcinoma
Characteristics Number of patients (n = 65)
Mean age (years)
 Median 65.63
 Range 42–107
Gender
 Male (93.85 %)
 Female (6.15 %)
Tumor stage
 Superficial (pta: ptl, TIS) 39 (60.00 %)
 Invasive (pt>2) 25 (38.46 %)
 Unknown 1 (1.54 %)
Tumor grade
 Low‑grade (GI) 24 (37.50 %)
 Medium‑grade (GII) 8 (12.50 %)
 High‑grade (GIII) 31 (48.44 %)
 Unknown 1 (1.56 %)
Bladder cancer recurrence
 Recurrence 28 (49.12 %)
 No recurrence 29 (50.88 %)
Bladder cancer progression
 Progression 11 (39.29 %)
 No progression 17 (60.71 %)
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RNA by measuring optical density values at 260 and 
280 nm with a nano-Drop ND-1000 Spectrophotometer 
(NanoDrop Technologies), the RNA was stored at −80 °C 
until use.
RT‑qPCR analysis
The mRNA levels of three genes, namely T-bet, GATA-
3, and Bcl-6, were determined by quantitative real-
time reverse-transcriptase PCR (RT-qPCR). In a first 
step, complementary DNA (cDNA) was reverse tran-
scribed from one microgram (1  μg) of total RNA, 
using a random oligonucleotide primer and M-MLV 
reverse transcriptase (Promega, USA), according to the 
manufacturer’s instructions. The cDNA was stored at 
−20  °C until use. For real-time PCR the SYBR Green 
PCR master mix (Applied Biosystems by life technolo-
gies) was used. PCR reactions were carried out on a 
7500 Fast Real-Time PCR System (Applied Biosystems) 
using the following conditions: an initial incubation at 
50  °C for 2  min then 95  °C for 10  min, followed by 45 
cycles of 95 °C for 15 s and 60 °C for 1 min. L32 mRNA 
was measured as the endogenous control (reference 
gene). All reactions were performed in triplicate. Prim-
ers for the amplification of the T-bet, GATA-3, Bcl-6, 
and L32 genes are described in Table 2, and were from 
Eurogentec.
Relative mRNA levels for each sample were quantified 
using the Ct approach (fluorescence threshold), normal-
ized to L32 mRNA as the standard. Expression of L32 
was used as an endogenous reference and expression of 
T-bet, GATA-3 and Bcl-6 target genes in each sample 
were normalized to the mean of all Ct (Ct Calib). Thus, 
the relative gene expression level was calculated as the 
normalized relative quantity: 
where ∆Ct target gene = Ct (calib-target gene)−Ct target 
gene and ∆Ct L32 = Ct (calib-L32)−Ct L32
NRQ =
2(�CT target gene)
2(�CT L32)
Statistical analysis
For basic statistical calculations, all gene expression lev-
els were treated as continuous variables. Differences in 
gene expression between different clinical statuses were 
analyzed by the Student test using Graph pad prism 6. 
The nonparametric Mann–Whitney U test was used 
for statistical evaluation of the differences between two 
independent groups. Survival time was analyzed using 
Kaplan–Meier curves. Overall survival (OS) was also 
compared using the log-rank and the Gehan–Wilcoxon 
tests. Differences were considered statistically significant 
when the p-value was <0.05.
Results
Outcome of patients upon surgery
The OS of our cohort of patients with bladder carcinoma 
was determined according to clinic-pathological fea-
tures. As expected, little or no mortality was observed 
in patients without recurrence and disease progression, 
compared to those with recurrence and progression 
(Fig. 1a, b). Similarly, patients with superficial and low- or 
medium-grade cancers had prolonged disease-free sur-
vival compared to those with invasive or high-grade dis-
ease (Fig. 1c, d).
T‑bet expression in bladder tumor
Expression of the Th1 transcription factor T-bet in blad-
der carcinoma was determined by real-time PCR as a 
function of the TNM histological stage of the disease. 
In invasive carcinoma (T2–T4), the level of T-bet was 
significantly higher (p  =  0.02) than in superficial non-
invasive bladder tumors (Tis, Ta, and T1) (Fig. 2a). Like-
wise, T-bet gene expression in patients with high-grade 
bladder cancer was significantly higher than that in 
patients with low- and medium-grade disease (p = 0.005) 
(Fig.  2b). There were no statistical differences between 
patients with or without recurrence (Fig. 2c), or with or 
without progression (Fig. 2d), suggesting that T-bet was 
not a marker of progression or recurrence of patients 
with bladder cancer. However, its reduction may be of 
good prognostic value. It is known that T-bet is responsi-
ble for the expression of IFNγ, a cytokine secreted by Th1 
[23] that exhibits anti-proliferative and pro-apoptotic 
mechanisms [24]. To determine whether T-bet positive 
cells are Th1, we evaluated the expression of interferon 
gamma (IFNγ) in tumors, by RT-qPCR. We found that 
there was no IFNγ expression in tumors, whatever their 
grade or stage (data not shown).
GATA‑3 expression in bladder cancer tissue
We next investigated by real-time PCR expression of the 
Th2-associated gene GATA-3 in bladder tumors. The 
Table 2 Sequences of primers for RT-PCR
F forward primer, R reverse primer
Target gene Oligonucleotide sequence (5ʹ→ 3ʹ)
L32 F‑ CTG CAG TCT CCT TGC ACA CTT
R‑TCT CCT GAA TGT GGT CAC CTG A
T‑bet F‑CCC CTT GGT GTG GAC TGA GA
R‑ACG CGC CTC CTC TTA GAG TC
GATA‑3 F‑GTC CTC CCT GAG CCA CAT CT
R‑GTG GTC CAA AGG ACA GGC TG
Bcl‑6 F‑ACC TGC GAA TCC ACA CAG GA
R‑AGT CGC AGC TGG CTT TTG TG
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expression level of GATA-3 in non-invasive carcinoma 
(Tis, Ta, and T1) was significantly higher (p  =  0.008) 
than in invasive bladder tumors (T2–T4) (Fig. 3a). Like-
wise, GATA-3 gene expression in patients with low- and 
medium-grade cancers was significantly higher than 
that in patients with high-grade bladder carcinomas 
(p  =  0.001) (Fig.  3b). On the other hand, GATA-3 lev-
els were not associated with recurrence or progression 
of non-muscle-invasive tumors (Fig.  3c, d). Limited to 
phenotyping of Th2 by the expression of GATA-3, these 
results suggest that reduced Th2 phenotype correlates 
with disease aggressiveness and a poor prognostic value.
Bcl‑6 expression in bladder cancer tissue
We next assessed whether Bcl-6 gene expression in blad-
der cancer was correlated to the clinic-pathological fea-
tures of patients. Real-time PCR analysis showed that 
Bcl-6 gene expression was higher in non-invasive blad-
der cancer tissue (Tis, Ta, and T1) than in invasive blad-
der tumors (T2–T4) (p = 0.0003) (Fig. 4a). Patients with 
low- and medium-grade carcinomas expressed the Bcl-6 
gene to high levels compared to patients with high-grade 
disease (p  <  0.0001) (Fig.  4b). Gene expression of the 
Bcl-6 gene was associated neither with disease pro-
gression nor with recurrence of bladder cancer tumors 
(Fig.  4c, d). Limited to the phenotyping of Tfh by the 
expression of Bcl-6, these results suggest that similarly to 
Th2, reduced tumor infiltration with Tfh cells correlates 
with disease aggressiveness and poor prognostic value.
Survival analysis
Next, we analyzed T-bet, GATA-3, and Bcl-6 levels in 
relation to OS of patients with bladder cancer. No cor-
relation was found between T-bet expression and patient 
survival (p  =  0.78) (Fig.  5A). However, high expres-
sion of GATA-3 (Fig. 5B) and Bcl-6 (Fig. 5C) were asso-
ciated with a better OS rate (p  =  0.04 and p  =  0.04, 
respectively).
The prognostic value of T‑bet, GATA‑3 and Bcl‑6 in the 
response to BCG treatment and in tobacco addicts
We further compared the expression of the three tran-
scription factors, T-bet, GATA-3 and Bcl-6 to treatment 
with BCG, in good or poor BCG responders. Real-time 
Fig. 1 Kaplan–Meir plots for overall survival (OS) according clinic‑pathological feature in patients with primary bladder cancer. Stratified survival 
curves for 65 patients were evaluated. a Patients with superficial and invasive stage *p = 0.03. b Patients with low and medium‑ and high‑ grade 
tumors *p = 0.01. c Patients with and without recurrence history *p = 0.04. d Patients with and without tumor progression ***p = 0.0002
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PCR analysis showed that there is no significant dif-
ference between the patient response to BCG and the 
expression of GATA-3 (Fig.  6a) and Bcl-6 (Fig.  6b), 
whereas the expression of T-bet is higher among patients 
who respond well to BCG as compared to non-respond-
ers (p = 0.02) (Fig. 6c). These results suggest that T-bet 
might be a predictor of the response to BCG therapy in 
patients with bladder cancer.
We also correlated the expression of these three genes 
with tobacco addiction of patients with bladder cancer. 
First, we showed that heavy smokers are poor responders 
to BCG (Fig.  7a). T-bet expression was not significantly 
different between heavy smokers and those who smoked 
less since their disease onset (Fig.  7b). In contrast, the 
expression of both GATA-3 (Fig. 7c) and Bcl-6 (Fig. 7d) 
was significantly lower in heavy smokers than in light 
ones (p = 0.01 and p = 0.03) respectively. These results 
suggest that smoking during treatment can be detrimen-
tal for disease outcome.
Discussion
The present study showed differences in levels of 
immune-related transcription factors between groups 
of patients suffering from bladder cancer, according to 
the histopathological features of the disease. Our data 
showed that high levels of T-bet were associated with 
Fig. 2 Relative expression of T‑bet in primary tumor biopsies. Histogram showing the expression levels of T‑bet according to clinic‑pathological fea‑
tures: a Statistical analyses of T‑bet expression between superficial and invasive histological stage of bladder cancer *p = 0.02. b Statistical analyses 
of T‑bet expression between low and high histological grade of bladder cancer **p = 0.005. c No correlation of T‑bet expression according to recur‑
rence. d No correlation of T‑bet expression according to tumor progression. L32 was used as the endogenous reference, and the expression of T‑bet 
target gene in each sample was normalized (as described in “Methods” section). All PCR samples were assessed in triplicate
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invasive carcinomas and patients with high-grade can-
cer. Although T-bet was originally cloned as a key tran-
scription factor, involved in the commitment of T helper 
(Th) cells to the Th1 lineage, it plays multiple roles in 
many subsets of immune cells, including innate lym-
phoid cells or type 1 (ILC1), B cell, Th17 and dendritic 
cells [25]. It appears that these Th1 cells are not active 
in tumors, which explains their association with high-
grade and stage cancer. In our study, we failed to detect 
IFNγ in tumors (data not shown). From this point of 
view, our results suggest that the increased expres-
sion of T-bet in the tumors in the absence of IFNγ may 
be considered as a marker of high-grade and advanced-
stage disease. Interestingly, we found that T-bet expres-
sion correlated with a good response to BCG therapy. 
This result could be explained by the BCG reactivation 
of unreactive Th1-type cells present in tumors, which is 
expected to induce local inflammation. Our results agree 
with those that suggest that the BCG therapy response 
is correlated with the magnitude of T-cell infiltration in 
patients’ populations [26]. Using a mouse tumor model, 
several groups have reported that BCG-mediated anti-
tumor activity requires a functional immune system, 
including CD4+ and CD8+ T lymphocytes [27]. Despite 
Fig. 3 GATA‑3 expression levels according to clinic‑pathological features: a Statistical analyses of GATA‑3 expression and pathological stage 
**p = 0.008. b Statistical analyses of GATA‑3 expression and pathological grade **p = 0.001. c No correlation between GATA‑3 expression and recur‑
rence. d No correlation between GATA‑3 expression and tumor progression
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the characterization of biomarkers predicting a response 
to BCG immunotherapy, few are promising as predictive 
markers of a response to BCG treatment [28].
Our results showed that the expression of GATA-3, a 
well-defined regulator of T helper2 (Th2) cell differentia-
tion, was significantly higher in superficial non-invasive 
carcinoma and in patients with low- or medium-grade 
disease. Our results did not allow the expression of 
GATA-3 to be associated with Th2, since we have not 
analyzed the expression of Th2-associated cytokines such 
as IL- 4, IL-5 and IL-13. It is also known that GATA-3 
regulates the specification and differentiation of many 
cell and tissue types, including: innate lymphoid cells 
(ILC), adipose tissue, endothelial cells, urothelium (a 
constituent of the bladder tumor environment) [29, 30]. 
Although we were unable to associate the expression of 
GATA-3 to Th2 or another type of cell, it remains pos-
sible that this transcription factor serves as a good prog-
nosis biomarker in bladder cancer, since its expression is 
associated with patient survival. We observed an inverse 
correlation between GATA-3 and T-bet expression in 
tumors. More precisely, in each sample, when T-bet 
expression was high, GATA-3 was low and vice versa. 
We can thus propose the hypothesis that the presence of 
Th1-type cells limits that of Th2-type. Evidence has accu-
mulated that cancer patients with non-small cell lung 
cancer [31], oral cancer [32], cervical cancer [33], and 
bladder cancer [34] have an imbalance in the Th1/Th2 
Fig. 4 Bcl‑6 expression levels according to clinic‑pathological features: a Statistical analyses of Bcl‑6 expression between superficial and invasive 
histological stages of bladder cancer ***p = 0.0003. b Statistical analyses of Bcl‑6 expression between low and high histological grades of bladder 
cancer ****p < 0.0001. c No correlation between Bcl‑6 expression and recurrence. d No correlation between Bcl‑6 expression and tumor progression
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axis. However, in these later reports, patients develop 
Th2 dominant status with deficiency in Th1. In the pre-
sent study, we not observed prevalence of status relative 
to each other, but rather the presence of one affects the 
expression of the other. In our results, no correlation was 
observed with GATA-3 expression and BCG response. 
Nunez-Netras et  al. [35] reported controversial results, 
showing correlation between high GATA-3 expression 
and good BCG response. This discrepancy could be 
related to the small number of patients and more par-
ticularly that all patients exhibited Tis stage, unlike our 
patients that had various stages and grades of the disease.
We also examined the expression of Bcl-6, which has 
been defined as an essential element for the develop-
ment of Tfh cells. This transcription factor has been 
described to be highly expressed in various human can-
cers. We found that the level of Bcl-6 was significantly 
higher in non-invasive carcinoma and in low- and 
medium-grade tumors than in invasive and high grade. 
Although overexpression of Bcl-6 was frequent in dif-
fuse large B cell lymphoma [36], its involvement in other 
cancer types was controversial. Our study is consist-
ent with a report indicating that Bcl-6 expression was 
significantly increased in transitional cell carcinoma of 
the urinary bladder, kidney and urethra [37]. In addi-
tion, Bcl-6 protein expression, determined by immu-
nohistochemical staining, correlated positively with 
grades 1 and 2 but not grade 3 of transitional cell car-
cinomas [37]. If we consider that the cells that express 
Bcl-6 are largely Tfh, our results are consistent with 
those indicating that impaired function of Tfh cells is 
associated with hepatocellular carcinoma progression 
[18]. Recent data also revealed that a detectable Tfh cell 
presence is associated with long-term positive clinical 
outcome in patients with either breast or colon cancer 
[17, 38]. Conversely, further studies revealed that Bcl-6 
Fig. 5 Kaplan–Meir plots for overall survival (OS) for T‑bet, GATA‑3, and Bcl‑6 gene expression in patients with primary bladder cancer. Stratified 
survival curves for 65 patients by relative gene expression evaluated by qPCR. A Survival of patients with low and high T‑bet expression levels. B 
Survival of patients with low and high GATA‑3 expression levels *p = 0.04. C Survival of patients with low and high Bcl‑6 expression levels *p = 0.04
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expression was associated with disease progression and 
poor survival of breast cancer patients [16]. To assign 
Bcl-6 to Tfh required the expression of markers associ-
ated with Tfh, such as: CXCR5, CXCL13 and IL-21 to 
be assessed. Considering the expression of Bcl-6 only in 
tumors, we can suggest that the expression of this tran-
scription factor is associated with a good prognosis in 
bladder cancer.
We also showed that the expression of both GATA-3 
and Bcl-6 but not T-bet was significantly lower in heavy 
smokers than in light ones, and heavy smokers are 
poor responders to BCG. Cigarette smoking is the best 
established risk factor for the development of blad-
der cancer and disease progression [39]. Many of the 
adverse effects of smoking might result from the abil-
ity of cigarette smoke to suppress the immune system 
[40]. To our knowledge, our study is the first to correlate 
tumor-infiltrating T cells to smoking in bladder cancer. 
It is worthy to note that among high smokers, the good 
BCG responders exhibited high T-bet expression, which 
is consistent with the good response to BCG of patients 
with high T-bet expression.
Fig. 6 Correlation of T‑bet, GATA‑3 and Bcl‑6 gene expression with response to BCG therapy. Expression of these transcription factors was evaluated 
by RT‑qPCR. a Statistical analyses of GATA‑3 expression for poor and good responders to BCG *p = 0.02. b Statistical analyses of Bcl‑6 expression for 
poor and good responders to BCG. c Statistical analyses of T‑bet expression for poor and good responders to BCG
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Conclusions
In summary, our results suggest that T-bet can be used as a 
predictive marker for good responses to BCG therapy. This 
conclusion could explain the fact that T-bet expression is 
not correlated with recurrence, progression nor survival, 
even though it is associated to high-grade and -stage in 
the diagnosis of bladder cancer, whereas an increase of 
GATA-3 and Bcl-6 expression are associated with a good 
survival rate. More detailed characterization of cell popu-
lations expressing these transcription factors might pro-
vide opportunities to eliminate protumoral cells in bladder 
cancer or harness antitumoral cells or compounds.
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